glp-1 in type 1 diabetes and the kidney: from physiology to pharmacology and outcomes GLP-1-based therapies for type 2

In purchasing these products, the customer acknowledges that there are hazards associated with their handling and use

Emerging multi-agonists such as retatrutide (GLP-1/GIP/glucagon triple agonist) and PTT-A (novel unimolecular peptide tetra-agonist targeting GLP-1, GIP, glucagon and amylin receptors) further expand this concept

Side effects may temporarily come back after each dose increase, then settle again once the dose remains stable

Individuals with pre-existing motility issues are much more sensitive to these changes

These symptoms could theoretically affect magnesium status through reduced intake or increased losses

So in this episode, we are gonna talk about GLP ones